| Autor: |
Yusuke Nakamura, Soo Chin Lee, Ching-Wan Chan, Mikael Hartman, Ern Yu Tan, Arata Shimo, Koichiro Tsugawa, Daisuke Shimizu, Kazuhiro Shimada, Akimitsu Yamada, Shinichi Baba, Yasuaki Sagara, Ayami Matsukata, Mai Onomura, Hisamitsu Zaha, Minoru Okazaki, Fukino Satomi, Hiroaki Shima, Goro Kutomi, Yoshie Hasegawa, Hiroshi Matsumoto, Kana Miyahara, Takashi Ishikawa, Hiroyuki Takei, Tomoko Takamaru, Chie Watanabe, Takashi Kuwayama, Sadako Akashi-Tanaka, Seigo Nakamura, Hitoshi Zembutsu |
| Rok vydání: |
2023 |
| Popis: |
Supplementary Figure S1. 　ER status in breast cancer tissues was associated with Ki-67 response after tamoxifen therapy. (A) Ki-67 response was lower in the tissues in which the proportion of ER-positive cells was less than 2/3 than in the tissues in which the proportion of ER-positive cells was 2/3 or more. (B) In Allred score, a semi quantitative system, that takes into consideration the proportion of positive cells (scored on a scale of 0-5) and staining intensity (scored on a scale of 0-3), tissues with score of 7 or less showed lower Ki-67 response than those with score of 8. Supplementary Figure S2. Correlation between Ki-67 response and tumor response after tamoxifen therapy. No significant tumor response was observed by short-term pre-operative tamoxifen therapy. No correlation was also observed between the tumor response and Ki-67 response (Pearson correlation coefficient; R = -0.12). Tumor response was measured in bi-directional maximum dimension using ultrasound. Supplementary Figure S3. Relationship between Ki-67 response and pathological response after tamoxifen therapy. The breast cancer tissues with no pathological response (Grade 0) showed significantly lower Ki-67 response than those with Grade 1a or more pathological response. Supplementary Figure S4. Association between CYP2D6 genotypes and Ki-67 labeling index in pre-treatment tissue. CYP2D6 genotype was not associated with Ki-67 labeling index in pre-treatment tissue. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
